Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects

NCT02742766 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02742766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02742766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
March 14, 2016
Completion date
June 16, 2017
Enrollment
104 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers